Related Experiment Videos
[Aggressive transformation and extramedullary tumor formation in IgA-lambda multiple myeloma].
M Tanigawa1, S Tamaki, A Fujieda
1Department of Internal Medicine, Yamada Red Cross Hospital.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|October 6, 2000
Summary
This case study details a rare, aggressive IgA-lambda multiple myeloma. Despite initial treatment responses, the patient experienced rapid progression and fatal complications, highlighting the challenges in managing fulminant multiple myeloma.
Area of Science:
- Hematology
- Oncology
Background:
- Multiple myeloma is a cancer of plasma cells, often presenting with bone pain, anemia, and renal dysfunction.
- IgA-lambda myeloma is a subtype characterized by the specific immunoglobulin and light chain produced by malignant plasma cells.
Observation:
- A 52-year-old woman presented with back and gluteal pain, anemia, hypercalcemia, and renal disorder.
- Initial diagnosis was IgA-lambda myeloma (stage IIIA), treated with VMMD-IFN therapy with temporary improvement.
- Disease progression included worsening pain, femur fracture, fever, elevated LDH, and extramedullary masses despite further treatment.
Findings:
- Bone marrow examination revealed atypical myeloma cells with specific immunophenotype (CD19-, CD38+, CD56+) and chromosomal abnormalities.
- Despite multiple treatment courses (VMMD-IFN, VAD), the patient experienced disease relapse and progression.
- The terminal stage was characterized by fulminant disease course with extramedullary involvement.
Implications:
- This case underscores the aggressive nature and poor prognosis of fulminant multiple myeloma.
- It highlights the need for novel therapeutic strategies for advanced and refractory myeloma.
- Understanding rare presentations is crucial for improving patient outcomes in hematologic malignancies.